» Articles » PMID: 26373212

Analysis of Factors Affecting Time in Therapeutic Range Control After Warfarin Administration

Overview
Journal Pharmazie
Specialties Pharmacology
Pharmacy
Date 2015 Sep 17
PMID 26373212
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The protective efficacy of warfarin for cardiogenic cerebral embolism has been established. However, warfarin is generally administered to only approximately 35% of the atrial fibrillation patients who required warfarin therapy. It has been reported that international normalized ratio (INR) control was carried out appropriately in < 50% of such patients. Therefore, from the viewpoint of prevention of the onset and recurrence of embolism, the maintenance of a stable anticoagulant level is necessary. In warfarin therapy, in addition to INR control, time in therapeutic range (TTR) also markedly affects the efficacy of warfarin therapy. Therefore, we classified patients into two groups on the basis of the cutoff TTR ≥ 65% at which the inhibitory effect of warfarin on stroke has been observed. We aimed to examine the association between INR and TTR with the correction of the therapeutic efficacy of warfarin by analyzing the factors leading to poor TTR control. The most valuable finding of this study is that marked fluctuations of brain natriuretic peptide levels in patients with complication of heart failure was a risk factor for poor TTR control. Identification of the factors leading to the poor TTR control is useful for making the decision to switch to other anticoagulants, such as dabigatran or apixaban, or to continue warfarin by correcting risk factors in atrial fibrillation patients receiving long-term warfarin therapy.

Citing Articles

Blood coagulation monitoring of patients with mechanical heart valve visiting Imam.

Montazeri N, Pourmehr S, Ziapour A, Moghadam R J Cardiothorac Surg. 2025; 20(1):68.

PMID: 39825431 PMC: 11740445. DOI: 10.1186/s13019-024-03188-7.


Anticoagulation Control and Major Adverse Clinical Events in Patients with Operated Valvular Heart Disease with and without Atrial Fibrillation Receiving Vitamin K Antagonists.

Zulkifly H, Pastori D, Lane D, Lip G J Clin Med. 2023; 12(3).

PMID: 36769789 PMC: 9917463. DOI: 10.3390/jcm12031141.


Clinical Impact of the Time in Therapeutic Range on Early Hospital Readmission in Patients with Acute Heart Failure Treated with Oral Anticoagulation in Internal Medicine.

Martin-Sanchez R, Lorenzo-Villalba N, Calvo-Elias A, Dubon-Peralta E, Chocron-Benbunan C, Cano-de Luque C Medicina (Kaunas). 2021; 57(4).

PMID: 33918627 PMC: 8069311. DOI: 10.3390/medicina57040365.


Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical heart valves: a tertiary hospital-based study in Botswana.

Botsile E, Mwita J Cardiovasc J Afr. 2020; 31(4):185-189.

PMID: 32181794 PMC: 8762804. DOI: 10.5830/CVJA-2020-006.


The Role of Clinical Variables and VKORC1 Polymorphism in Efficacy and Stability of Acenocoumarol in Neurological Patients.

Kumar S, Dubey A, Kalita J, Misra U J Neurosci Rural Pract. 2018; 9(2):186-192.

PMID: 29725167 PMC: 5912022. DOI: 10.4103/jnrp.jnrp_306_17.